on PREDILIFE (EPA:ALPRE)
PREDILIFE Half-Yearly Results and Outlook for 2024
On October 28, 2024, PREDILIFE published its financial results for the first half of 2024. Specializing in disease risk prediction, the company recorded stable revenues of €157,900, despite an uncertain economic context. Strategic partnerships, particularly with recognized brokers such as Diot Siaci and Mercer, have strengthened its position in the market for predictive assessments for employees.
Furthermore, the company continues its investments in MammoRisk®, with the MyPebs clinical trial. External evaluations have estimated the potential value of this activity at €207.3 million.
Stéphane Ragusa, CEO, expresses his confidence in the expected growth in turnover for 2024, affirming the efficiency and growing potential of the offer.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PREDILIFE news